Merck KGaA et al. v. Hopewell Pharma Ventures, Inc. et al.

I'll research this case thoroughly before drafting the overview.

Let me gather more on the IPRs, the Federal Circuit appeal, and market context.

Case Overview and Background

The parties. This is a Hatch-Waxman ANDA action, not an NPE suit: the plaintiffs are all operating-company affiliates of Merck KGaA, Darmstadt, Germany (distinct from the U.S. "Merck" / MSD). Merck KGaA is the German science-and-technology group; Merck Serono S.A. is its Swiss biopharma subsidiary; and Ares Trading S.A. is a Swiss affiliate that holds assets in the group's healthcare portfolio. Their adversary is a set of generic developers: Hopewell Pharma Ventures, Inc., which filed ANDA No. 215547 for generic cladribine 10 mg tablets and is the lead/original defendant here; Aurobindo Pharma USA, Inc. and Aurobindo Pharma Ltd.; and Apotex Inc. and Apotex Corp. (the latter two were added in separately docketed, later-consolidated actions, Nos. 1:23-cv-00039 and 1:23-cv-00655). Notably, Hopewell is a comparatively small, litigation-forward ANDA sponsor rather than a classic operating company — sources characterize it as a pharmaceutical-development entity that, unusually for an ANDA defendant, took the offensive by filing its own IPRs against the patents it was accused of infringing.

The accused product and technology. The product at issue is MAVENCLAD® (cladribine) tablets — Merck's oral short-course therapy for highly active relapsing multiple sclerosis, and a genuine blockbuster (2024 net sales of roughly €1.06 billion, up ~12% organically, per Merck KGaA's 2024 annual report). Each defendant submitted an ANDA seeking approval to market generic cladribine 10 mg tablets with labeling that mirrors Mavenclad's dosing instructions, and Merck alleges that prescribing and use of those generics in accordance with their proposed labels would infringe the asserted method-of-treatment claims under 35 U.S.C. §§ 271(a)–(c), with the ANDA submissions themselves constituting technical acts of infringement under § 271(e)(2). Beyond the marketed indication, the case also reaches cladribine's use in progressive forms of MS.

The patents. Three patents were named in the original October 17, 2022 complaint, though only two remain in play. The '947 patent (U.S. 7,713,947), "Cladribine Regimen for Treating Multiple Sclerosis" (issued May 2010), claims a four-phase oral cladribine dosing schedule for MS: an induction period of about 2–4 months reaching ~1.7–3.5 mg/kg, an 8–10 month cladribine-free interval, a 2–4 month maintenance period at ~1.7 mg/kg, then a second drug-free period. The '903 patent (U.S. 8,377,903) shares that specification and claims a substantively identical regimen (representative claim 17), directed to relapsing-remitting or early secondary progressive MS. The '919 patent (U.S. 10,849,919), "Cladribine Regimen for Treating Progressive Forms of Multiple Sclerosis" (owned by Ares Trading), claims oral cladribine dosing to treat PPMS/SPMS — for example, a cumulative ~3.5 mg/kg over two years delivered as two annual courses. Plaintiffs initially asserted the '919 patent but, as the claim-construction record confirms (D.I. 141 at 1–2), later stopped asserting it against any defendant, leaving the '947 and '903 patents as the live patents-in-suit.

Procedural Posture and Venue

The case sits in the District of Delaware before Judge Gregory B. Williams (the "GBW" suffix), with pre-trial matters — including the January 30, 2024 Markman hearing and the resulting June 13, 2024 Report and Recommendation (D.I. 141, adopted Aug. 28, 2024) construing "induction period" and "maintenance period" — handled by Magistrate Judge Christopher J. Burke (the "CJB" suffix). Delaware is the dominant Hatch-Waxman venue: it is the incorporation home of many brand and generic manufacturers, its judges have deep ANDA and patent expertise, and its local rules and case-management practices produce comparatively predictable schedules — factors that make it a magnet for exactly this kind of multi-defendant, consolidated generic-cladribine litigation. The case is currently stayed, but the stay is not a conventional litigation pause: it is a stay pending IPR appeals. Hopewell successfully petitioned for inter partes review of the '947 and '903 patents (IPR2023-00480 and IPR2023-00481; it also filed IPR2023-00482 against the '919 patent). On September 18, 2024, the PTAB issued final written decisions holding all challenged claims unpatentable as obvious over the Bodor international application (WO 2004/087101) in view of the 1998 Stelmasiak paper. The court granted Hopewell's emergency stay on December 23, 2024 (D.I. 223) and imposed a global stay covering the remaining defendants on January 16, 2025. On October 30, 2025, the Federal Circuit affirmed in a precedential opinion, Merck Serono S.A. v. Hopewell Pharma Ventures, Inc., Nos. 2025-1210, -1211 (Fed. Cir. Oct. 30, 2025) (Linn, J., joined by Hughes and Cunningham, JJ.), a companion to Merck Serono S.A. v. TWi Pharmaceuticals, Nos. 2025-1463, -1464. On December 4, 2025, Judge Williams denied Hopewell's emergency motion to lift the tolled 30-month regulatory stay (D.I. 245 / 252; 2025 WL 3485555). RECAP/CourtListener docket entries also reflect a January 2026 judgment and termination entry (D.I. 267), which appears to follow issuance of the Federal Circuit's mandate; because the case file's operative status is "stayed" and the docket detail is thin, I would treat that termination entry as docket-sourced and not independently confirmed.

Why the Case Is Notable

Three features make this docket worth tracking. First, it is a leading IPR-linkage case. An ANDA defendant used the PTAB to invalidate the very patents asserted against it and then leveraged that win to obtain — and, later, to try to unwind — district-court and regulatory stays, a strategy that increasingly defines modern Hatch-Waxman defense. Second, the 30-month-stay tolling ruling created a striking intra-generic split. The court tolled the statutory stay of FDA approval as to Hopewell (the IPR petitioner) but declined to toll Apotex's, so a later filer like Apotex could potentially reach the market at risk while the generics' own IPR challenger waited — prompting Hopewell's unsuccessful argument that this worked "irreparable competitive harm." Judge Williams held he "lack[ed] the power" to shorten the statutory stay absent a merits decision or bad-faith failure to cooperate, and that any Merck delay in the IPR appeals was not a failure to expedite the infringement action. (The opinion also flags a separate 180-day-exclusivity dispute involving Accord's ANDA.) Third, the Federal Circuit's precedential "by another" holding — that under pre-AIA §§ 102(a)/(e) any incongruity in inventive entity between a prior reference and the patent, whether inventors are added or subtracted, renders the reference "by another," so that overlapping but non-identical inventorship does not disqualify it — is a doctrinal rule with relevance well beyond cladribine, and it traces back to the Serono–IVAX joint-development relationship of the early 2000s. The commercial stakes are considerable: Mavenclad's U.S. patent cliff is widely modeled around late 2026, and with the asserted '947 and '903 claims invalidated and affirmed, the litigation largely turns on the timing of generic entry rather than liability.

Sourcing / caveats. Party descriptions, patent scopes, the claim-construction and stay history, and the IPR/PTAB and Federal Circuit outcomes are well supported (D.I. 141; D.I. 223; D.I. 245; Robins Kaplan's Hatch-Waxman bulletin; Fish & Richardson and White & Case/A&O Shearman/Alston & Bird analyses; CourtListener/RECAP; Merck KGaA 2024 Annual Report). Plaintiff-side counsel appears to be Morris, Nichols, Arsht & Tunnell (per DrugPatentWatch), but I could not independently verify the full trial and appellate counsel rosters, so those are not stated here. I also found no reliable public source confirming Hopewell's ownership structure or funding; descriptions of it as a "biotechnology company" appear only in secondary case summaries, so treat any characterization of it as an NPE/PAE as unsupported — on the record available, it is simply an ANDA filer.

I'll research this case thoroughly using web search.

Let me gather more detail on the docket, IPRs, and the Federal Circuit appeal.

Let me get the full docket and more specifics on early motions.

Merck KGaA v. Hopewell Pharma Ventures — Chronology of Key Legal Developments

Case: Merck KGaA, Merck Serono SA & Ares Trading SA v. Hopewell Pharma Ventures, Inc., Aurobindo Pharma USA, Inc., Aurobindo Pharma Ltd., Apotex Inc. & Apotex Corp., No. 1:22-cv-01365-GBW-CJB (D. Del.)
Product: MAVENCLAD® (cladribine) 10 mg tablets, an oral MS therapy
Patents: U.S. 7,713,947 ('947), 8,377,903 ('903), 10,849,919 ('919)
Bench: District Judge Gregory B. Williams (GBW); Magistrate Judge Christopher J. Burke (CJB), to whom all pretrial matters through expert discovery were referred (D.I. 50)

Note on posture: the case metadata furnished to me records the matter as "stayed." That was accurate from December 2024/January 2025 forward, but the docket reflects that the case was terminated in early 2026 after the Federal Circuit mandate issued. Both phases are covered below; where a fact is only weakly sourced I flag it.

---

1. Filing and initial pleadings (2022)

Related/consolidated actions. Merck filed parallel ANDA suits that were consolidated into 22-1365: Merck KGaA v. Accord Healthcare, Inc., No. 1:22-cv-00974-GBW; Merck KGaA v. Aurobindo Pharma USA, Inc., No. 1:23-cv-00039-GBW; and Merck KGaA v. Apotex Inc., No. 1:23-cv-00655-GBW. Consolidation is confirmed at Merck KGaA v. Hopewell Pharma Ventures, Inc., 2024 WL 2973034, at *1 n.1 (D. Del. June 13, 2024), adopted, 2024 WL 3967463 (D. Del. Aug. 28, 2024).

Narrowing of the case. Plaintiffs ceased asserting the '919 patent against any defendant — expressly noted in the claim-construction R&R (D.I. 141, filed 2024-06-13). The '919 patent therefore drops out of the merits, leaving the '947 and '903 patents as the asserted patents.

---

2. Parallel PTAB proceedings (filed 2023) — the dispositive track

This litigation was effectively decided at the PTAB, not in Delaware.

• IPR2023-00480 — Hopewell Pharma Ventures, Inc. v. Merck Serono S.A., challenging claims 36, 38, 39 and 41–46 of the '947 patent.
• IPR2023-00481 — Hopewell Pharma Ventures, Inc. v. Merck Serono S.A., challenging claims 17, 19, 20 and 22–27 of the '903 patent.
• Both petitions were filed around 2023-02-10 (Paper and exhibit records dated 02-10-2023). A third Hopewell petition, IPR2023-00482, also appears in PTAB records; I could not confirm from the sources retrieved which patent it targeted (likely the '919), and I therefore do not assert its scope.
• Real parties in interest: Merck Serono SA, Merck KGaA and Ares Trading SA (Merck Serono and Ares Trading are wholly owned subsidiaries of Merck KGaA) (IPR2023-00481 Mandatory Notice).
• Third-party challenger TWi Pharmaceuticals, Inc. filed its own IPRs on the same patents (e.g., IPR2023-00049), producing the companion appeal addressed below.

Final Written Decisions — 2024-09-18. The Board held all challenged claims of both patents **

I'll search multiple angles to locate press coverage of this litigation.

Let me dig into specific outlets and the appellate ruling.

Now let me look for market/trade coverage on the generic launch implications and any mainstream reporting.

Press coverage of Merck KGaA v. Hopewell Pharma Ventures is real but confined almost entirely to the legal trade and pharmaceutical business press. I found no reporting from Reuters, Bloomberg Law, Ars Technica, The Verge, or other mainstream/general-interest outlets, and no EFF or Patently-O piece specific to this case. The substantive coverage clusters around two events: the Federal Circuit's precedential Oct. 30, 2025 affirmance of the PTAB's invalidation of the '947 and '903 patents, and the resulting commercial collapse of Mavenclad's U.S. exclusivity. District-court developments were covered mainly through case pages and law-firm bulletins rather than reported articles.

Law360 maintains a litigation tracker for the appeal and reported on 2025-10-30 that "the Federal Circuit sided with generics makers Thursday and upheld the Patent Trial and Appeal Board's invalidation of claims in two Merck KGaA patents on the blockbuster multiple sclerosis drug Mavenclad, while clarifying how to treat invalidity arguments that involve overlapping inventors." Law360 also tracked the district case, reporting on 2025-12-05 that "a Delaware federal judge has shot down Hopewell Pharma Ventures' bid to lift a regulatory stay on approval of its planned generic version" of Mavenclad, and later that Merck (Dec. 1, 2025) asked the Federal Circuit to rehear the case on the theory the ruling "creates a rule where inventors' work can later be used against them," a request the court refused on Jan. 22, 2026. IPWatchdog published a 2025-10-30 analysis by Eileen McDermott framing the decision as a precedential clarification of pre-AIA §§ 102(a)/(e), quoting the court's holding that "when the patented invention is the result of the work of joint inventors, the portions of the reference disclosure relied upon must reflect the collective work of the same inventive entity identified in the patent to be excluded as prior art," and noting the opinion (authored by Judge Linn) reaffirmed In re Land against Merck's reliance on Applied Materials v. Gemini. Wolters Kluwer's VitalLaw ran an IP Law Daily summary on 2025-10-30 headlined "Merck Serono's cladribine patents correctly invalidated as obvious," and law-firm client alerts from Schwabe ("Case of the Week" in Latest Federal Court Cases) and A&O Shearman's IP blog (also syndicated via Lexology) dissected the Bodor "six-line disclosure" and the evidentiary fight over whether inventor Dr. De Luca contributed to it.

On the business/market side, Fierce Pharma included Mavenclad in its "top 10 drugs losing US exclusivity in 2026" report, putting 2025 North American sales at $716 million (€635 million) and stating that "a court decision last October found two patents on the drug invalid, which could allow more generic drugmakers to enter the market, according to Merck KGaA's financial materials"; it also noted the FDA's generic approval letter to Apotex and that Merck "alluded to a 'restructuring' related to Mavenclad" in a recent investor presentation without further detail. A Chinese-language trade article on 163.com (2026-03-06) reported that Merck's 2026 guidance states it expects no U.S. Mavenclad sales after March 2026 because of generic competition, that Apotex's generic was approved and launched in late 2025, and that another filer has tentative approval with three more developing products; it attributes to Merck executive "Beckmann" a statement at an analyst meeting that the company preferred to be explicit rather than guess at generic entrants' timing (this piece cites a Fierce Pharma article titled "After generic defense fails, Merck KGaA expects no US Mavenclad sales after March," which appeared in the article's reference list but which I could not independently open). On the defendant's side, Sterne Kessler issued a 2025-11-04 release quoting Hopewell co-founder/CEO Dr. Jonathan Embleton — "We're very pleased that the Federal Circuit upheld the PTAB's thoughtful decisions" — and disclosed that Hopewell was funded by litigation financier GLS Capital; a second firm release dated 2026-01-26 confirmed the denial of rehearing.

Where accounts differ or go beyond the record: the appellate docket numbers are reported inconsistently — VitalLaw cites Nos. 2024-1745/-1746 while Schwabe and the natlawreview/Lexology alert cite Nos. 2025-1210/-1211 (Case No. 25-1210), and the appeal caption itself is Merck Serono S.A. v. Hopewell Pharma Ventures, Inc. rather than the district-court caption. The financial-impact framing (Merck booking zero U.S. Mavenclad revenue, a "restructuring," European exclusivity running to roughly August 2027) comes from analyst-facing statements and investor materials rather than from any court filing, and the German-language market commentary I encountered appeared in investor-forum reposts rather than identifiable journalism, so I would not treat its revenue figures as independently verified. Notably, no outlet reported any damages figure, settlement, verdict, or license terms in the district case — consistent with the record, since the D. Del. action was globally stayed and terminated without trial (the CourtListener docket shows Judge Williams' Dec. 4, 2025 memorandum opinion denying Hopewell's emergency motion to lift the regulatory stay, and a Jan. 29, 2026 judgment terminating the case). Law-firm newsletters such as Robinson + Kaplan's GENERically Speaking provide the most granular account of the stay mechanics — including that the court tolled Hopewell's 30-month stay but declined to toll Apotex's, and that the court held it lacked authority to shorten the statutory stay absent a Federal Circuit mandate — but these are attorney-authored bulletins rather than independent press.

Sources

• Merck KGaA et al v. Hopewell Pharma Ventures, Inc., et al.
• Sterne Kessler Delivers Another Federal Circuit Victory for Hopewell Pharma in Ongoing Patent Dispute
• Merck KGaA v. Hopewell Pharma Ventures, Inc.
• Merck KGaA v. Hopewell Pharma Ventures, Inc., 1:22-cv-01365 - CourtListener.com
• cladribine drug patent court cases and PTAB cases for small molecule and biologic drugs - Last Updated: April 7, 2026
• small molecule and biologic drug patent lawsuits involving MERCK KGAA - Last Updated: May 18, 2026
• Merck Serono S.A. v. Hopewell Pharma Ventures, Inc.
• Complete inventive entity required to avoid “by another” prior art under pre-AIA § 102(e) - Register now for your free, tailored, daily legal newsfeed service.
• Merck KGaA et al v. Hopewell Pharma Ventures, Inc., et al.
• Merck KGaA v. Aurobindo Pharma | Patent Lawsuit 1:23-cv-00039 - Merck KGaA v. Aurobindo Pharma, Ltd.
• CourtListener.com Custom Search Feed - CourtListener
• The Interplay of Patent Term Extension (PTE) and Reissue: Merck v. Aurobindo and Its Implications, Part I

I'll research the plaintiff-side counsel of record using multiple searches.

Good initial hits. Let me pin down the full appearance roster in the district court, plus the later-filed consolidated actions.

Let me dig into the district court appearance list (WilmerHale's role) and the Apotex case counsel.

Plaintiff-Side Counsel of Record — Merck KGaA, Merck Serono S.A., Ares Trading S.A. v. Hopewell Pharma Ventures, Inc., No. 1:22-cv-01365-GBW-CJB (D. Del.)

This fills in the open item from the case-overview section (which flagged Morris Nichols as probable but unverified). The plaintiff side runs on a two-firm structure: Morris, Nichols, Arsht & Tunnell LLP as Delaware counsel of record, and Wilmer Cutler Pickering Hale and Dorr LLP as the plaintiffs' life-sciences patent counsel — the same WilmerHale team that defended the patents in the Hopewell IPRs and prosecuted the Federal Circuit appeal.

1. Delaware counsel of record (Morris, Nichols, Arsht & Tunnell LLP, Wilmington, DE)

These are the two attorneys entered on the D. Del. docket as representing all three plaintiffs (and as counsel for the counter-defendants on Hopewell's counterclaims):

Sourcing: the docket sheet for 1:22-cv-01365-GBW reproduced as Exhibit 1045 in IPR2023-00482 and the parallel Exhibit 1044 for 1:23-cv-00039 (both showing Blumenfeld as lead and Tigan as appearing attorney for Merck KGaA, Merck Serono SA and Ares Trading SA); Tigan's signatures on D.I. 7 (summons returned executed), D.I. 11, and the 2024 discovery notices of service; and Tigan's Morris Nichols bio (PDF). The same two-attorney firm roster appears for plaintiffs in the Aurobindo case (1:23-cv-00039) on Justia, UniCourt, Patexia and CourtListener docket summaries.

Caution: the docket-sheet snapshot I relied on is an exhibit filed in the IPRs in February 2023, so it is a vintage capture. The entries themselves date to 2022–23, but Tigan's name continues to appear as plaintiffs' filer through the 2024 discovery period on the RECAP/CourtListener docket, so the roster appears stable.

2. Plaintiffs' principal patent counsel (Wilmer Cutler Pickering Hale and Dorr LLP)

WilmerHale acted for Merck Serono S.A. (and the Merck side generally) in the linked PTAB proceedings and on appeal, and at least one member of the team appeared for plaintiffs in the district court:

I'll research defense counsel across the docket, firm announcements, and court opinions.

Good initial data. Now let me dig into the specific docket entries and the Aurobindo/Apotex representations.

Now let me pin down Apotex's counsel and verify the Aurobindo representation in this specific case.

Answer, with sourcing and explicit confidence flags. Note that the tool budget ran out before I could fully verify Apotex's national/lead trial counsel, so I mark confidence per entry rather than papering over gaps.

---

1. Confirmed counsel of record, by defendant

Hopewell Pharma Ventures, Inc. — highest-confidence entry (docket-sourced)

The fullest list of record for Hopewell appears in the Civil Docket for 1:22-cv-01365-GBW as captured in February 2023 (Exhibit 1045 to Hopewell's IPR2023-00482 petition, reproduced in the Docket Alarm PTAB file set), and is corroborated by Sterne Kessler's own press releases.

Sterne Kessler's own releases identify additional team members (Directors Olga Partington, Ph.D. and Richard Crudo; Counsel Tyler Liu; plus attorneys Pratibha Khanduri, Madeleine Bond, and patent agent Sarah Leesman) on the IPR/appellate side. Those are firm-announcement-sourced, not confirmed district-court appearances.

Financial context (not counsel, but relevant): Hopewell's litigation funder is GLS Capital, per repeated Sterne Kessler releases quoting Hopewell CEO/founder Dr. Jonathan Embleton.

⚠️ Correction flag on prior section's sourcing. The prior generated sections noted that plaintiff-side counsel "appears to be Morris, Nichols, Arsht & Tunnell (per DrugPatentWatch)" — that is correct and now confirmed by the docket (Jack B. Blumenfeld, lead; Jeremy A. Tigan). Related: filings in the IPRs list Wilmer Cutler Pickering Hale and Dorr (Emily R. Whelan, Mark C. Fleming, James M. Lyons, David B. Bassett, Deric Geng, Cindy Kan; alias "WHMerckMavencladIPRs@wilmerhale.com") — the Merck-specific alias plus the Federal Circuit caption ("Attorneys for Appellant Merck Serono S.A.") establish WilmerHale as Merck's IPR/appellate counsel, not Hopewell's. Do not attribute WilmerHale or Wenli Gu (the WilmerHale name surfacing on an Ex Parte attorney page cross-referenced to 1:22-cv-01365) to the defense side.

Aurobindo Pharma USA, Inc. and Aurobindo Pharma Ltd. — consolidated from C.A. No. 1:23-cv-00039-GBW (filed Jan. 13, 2023)

Docket-sourced (Exhibit 1044 to the IPR2023-00482 petition; consistent with the Justia/UniCourt docket and D.I. 9 in that case):

⚠️ Caveat: Aurobindo runs different counsel combinations in other matters (Greenberg Traurig's Roger B. Kaplan / Jason Kishin / Aaron Van Nostrand / Brian T. Feeney in a Pennsylvania action; Wiggin and Dana in a mandamus/